SARS-CoV-2 neutralizing antibodies

CORAT always welcomes joint research projects and alliances to explore new avenues for the development of targeted SARS-CoV-2 therapies.

COR-101 Program

Corat is actively looking for strategic partners supporting us to advance our lead product COR-101 as fast as we can into the market. We are currently looking for partners for the commercial manufacturing and for marketing & sales of our innovative product. We will be seeking approval for COR-101 in 2022 to treat and help patients suffering from COVID-19.

We are open for licensing and/or co-development agreements with pharmaceutical partners globally or for territorial licenses.

For further information please contact us.